Clinical Trial

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

Study acronym: TRI Pro
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-07
Trial Details
NCT Number NCT07589634
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 230 participants
Start Date 2026-07-20
Primary Completion 2027-12-31 (estimated)
Study Completion 2030-11-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-06